Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split Dose Study of Rhenium-188-HEDP in Hormone-Refractory Prostate Cancer with Bone Metastases
2007-004545-15Phase 2Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- Sep 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rhenium-188-HEDP in prostate cancer (PCa) and bone metastases, sponsored by University Medical Center Utrecht. Started Sep 2008; status: terminated.
02
Drugs
Rhenium-188-HEDP
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on 2007-004545-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004545-15.